← Leaderboards
Philip C Johnson
University Of Texas Hlth Sci Ctr Houston
$60,456
Attributed
$60,456
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$60,456 · 4
By mechanism
M01$60,456 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Michael C Lorenz$12,581,222
- John L Spudich$21,092,923
- Danielle A Garsin$10,870,643
- Rodrigo Morales$8,127,531
- Tatiana Barichello$1,599,272
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCombination ChemotherapyHuman Therapy EvaluationAids TherapyHuman SubjectZidovudineAntiaids AgentDrug Screening /EvaluationHiv InfectionsLamivudineReverse Transcriptase InhibitorsIndinavirVirus RnaHelper T LymphocyteBacterial MeningitisAmphotericin BLeukocyte CountMicroorganism Disease ChemotherapyOpportunistic InfectionsCryptococcusDelavirdinePhenotypeGenotypeFluconazole
Grant awards (6)
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS$0
M01 · FY2002 · RR
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS$0
M01 · FY2001 · RR
AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS$15,114
M01 · FY2000 · RR
AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PATIENTS$15,114
M01 · FY2000 · RR
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS$15,114
M01 · FY2000 · RR
COMBINATION TRIAL OF DLV, ZDV AND 3TC AS INITIAL OR FOLLOWUP THERAPY (PART II)$15,114
M01 · FY2000 · RR